STOCK TITAN
  1. Home
  2. Sec-filings
  3. EWTX
  4. [Form 4] Edgewise Therapeutics, Inc. Insider Trading Activity

Director Jonathan Fox of Edgewise Therapeutics (EWTX) receives 319-share stock grant

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Fox Jonathan C reported acquisition or exercise transactions in this Form 4 filing.

Edgewise Therapeutics director Jonathan C. Fox received a grant of 319 shares of Common Stock. The shares were awarded at a price of $0.00 per share as a compensation-related grant, not an open-market purchase. Following this award, Fox directly holds 24,833 shares of Edgewise Therapeutics common stock.

Positive

  • None.

Negative

  • None.
Insider Fox Jonathan C
Role null
Type Security Shares Price Value
Grant/Award Common Stock 319 $0.00 --
Holdings After Transaction: Common Stock — 24,833 shares (Direct, null)
Footnotes (1)
Shares granted 319 shares Common Stock grant to Jonathan C. Fox
Grant price $0.00 per share Reported price for 319-share award
Shares held after grant 24,833 shares Total direct holdings following transaction
Common Stock financial
"security_title: "Common Stock""
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
Grant, award, or other acquisition financial
"transaction_code_description: "Grant, award, or other acquisition""
Form 4 regulatory
"INSIDER FILING DATA (Form 4)"
Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Fox Jonathan C
(Last)(First)(Middle)
C/O EDGEWISE THERAPEUTICS, INC.
1715 38TH STREET
(Street)
BOULDER COLORADO 80301
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Edgewise Therapeutics, Inc. [ EWTX ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
07/01/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock07/01/2026A319A$0.0024,833D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
Remarks:
Consists of restricted stock units granted and released to the reporting person on July 1, 2026, as a Quarterly Retainer Award pursuant to Section 2.4 of the Edgewise Therapeutics, Inc. Outside Directors Compensation Policy, as amended.
/s/ John R. Moore, Attorney-in-Fact for Fox Jonathan C07/01/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Edgewise Therapeutics (EWTX) report for Jonathan C. Fox?

Edgewise Therapeutics reported that director Jonathan C. Fox received a grant of 319 shares of Common Stock. The award was recorded at $0.00 per share as compensation, rather than a market purchase, and increased his direct holdings in the company.

How many Edgewise Therapeutics (EWTX) shares does Jonathan C. Fox now hold?

After the latest grant, Jonathan C. Fox directly holds 24,833 shares of Edgewise Therapeutics Common Stock. This total includes the newly awarded 319-share grant reported in the Form 4 insider transaction filing for the company.

Was the Edgewise Therapeutics (EWTX) insider transaction a market buy or a compensation grant?

The transaction was a compensation-related grant, not a market buy. Jonathan C. Fox received 319 shares of Common Stock at a reported price of $0.00 per share, classified as a “Grant, award, or other acquisition” in the insider filing details.

What transaction code was used in the Edgewise Therapeutics (EWTX) Form 4 for Jonathan C. Fox?

The Form 4 for Jonathan C. Fox used transaction code "A," which stands for "Grant, award, or other acquisition." This code indicates the 319-share increase in his Common Stock holdings came from a stock award rather than an open-market transaction.

Does the Edgewise Therapeutics (EWTX) Form 4 show any stock sales by Jonathan C. Fox?

The Form 4 does not show any stock sales by Jonathan C. Fox. It reports a single acquisition transaction: a grant of 319 shares of Common Stock at $0.00 per share, increasing his direct ownership to 24,833 shares in total.